ANN ARBOR, Mich. — Daniel F. Hayes, M.D., clinical director of the breast oncology program at the University of Michigan Comprehensive Cancer Center, was elected president of the American Society of Clinical Oncology.
The three-year appointment begins with Hayes becoming president-elect on June 1, 2015. He will serve as president from June 1, 2016, to May 31, 2017, and will be immediate past-president for a year after that.
ASCO is the largest and one of the most influential oncology professional societies, with more than 35,000 members around the globe.
“I’m honored to be elected incoming president of ASCO, which has had such a major influence on my professional career,” says Hayes, the Stuart B. Padnos Professor of Breast Cancer Research at the University of Michigan Comprehensive Cancer Center.
His term will focus on issues including new strategies for health care reform; the development of CancerLinQ and other efforts to improve quality and value in cancer care; personalized cancer care; and reducing disparities in cancer treatment throughout the world.
“I look forward to working with ASCO leadership and staff on these critical initiatives within the oncology community. ASCO is uniquely positioned to tackle these issues head-on, and I look forward to being part of this exciting time in the life of the society,” Hayes says.
Hayes has previously served on the ASCO board of directors and has chaired several ASCO guideline committees and its scientific program committee. He is an expert in the field of breast cancer. In addition to his clinical expertise, he directs breast cancer research that is translated to the clinic, including new treatments, and the development, evaluation and clinical use of tumor markers.
Founded in 1964, ASCO’s mission is improving cancer care through scientific meetings, educational programs and peer-reviewed journals. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which funds ground-breaking research and programs that make a tangible difference in the lives of people with cancer.